Thermo Fisher Scientific

Autolus Therapeutics announces publication in Blood Cancer Journal

Retrieved on: 
Monday, March 11, 2024

LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled ‘Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.’ 1

Key Points: 
  • LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled ‘Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.’ 1
    Diagnosing leukemic T-cell malignancies poses challenges due to their resemblance to reactive T-cells.
  • In the paper published by Pedro Horna of Mayo Clinic in collaboration with Autolus, the authors introduce a unique approach for identifying T-cell neoplasms by flow cytometry1.
  • This method adopts the recently described monoclonal antibodies targeting TRBC1 and TRBC22, 3, to assess for TRBC-restriction as a surrogate of clonality.
  • The strategy mirrors the routine and broadly adopted analysis of kappa and lambda immunoglobulin chain restriction for the identification of B-cell malignancies.

Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers

Retrieved on: 
Wednesday, March 6, 2024

The Company’s mRNA for Life™ is a one-of-the-kind noninvasive at-home sceening test for genes that could be associated with cancer.

Key Points: 
  • The Company’s mRNA for Life™ is a one-of-the-kind noninvasive at-home sceening test for genes that could be associated with cancer.
  • This test allows a person to make themselves a priority and could be a signal to seek a medical examination.
  • The Company selected for measurement 48 distinct mRNA genes in stored specimens from patients afflicted with breast, bladder or colorectal cancer.
  • mRNA levels were analyzed using machine learning artificial intelligence (AI) to identify markers of genetic expression involved in separate cancers.

Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook

Retrieved on: 
Monday, March 4, 2024

MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2023.

Key Points: 
  • MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2023.
  • Gross margin was 62.7% in the fourth quarter of 2023, compared to 56.8% in the prior year period.
  • Operating expense was $26.1 million for the fourth quarter of 2023, compared to $29.6 million in the prior year period; a decrease of 11.8%.
  • Akoya will host a conference call today, March 4, 2024, at 5:00 p.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results.

Thermo Fisher Scientific Launches CorEvitas Clinical Registry in Generalized Pustular Psoriasis

Retrieved on: 
Friday, March 8, 2024

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP).

Key Points: 
  • Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP).
  • This registry, which is open to enrollment, is CorEvitas’ 10th syndicated disease registry and addresses an unmet need for real-world evidence (RWE) related to the clinical and patient-reported outcomes of patients with GPP.
  • Thermo Fisher acquired CorEvitas, a leading provider of gold-standard real-world evidence solutions, in August 2023.
  • The registry was launched with clinical guidance from two leading GPP clinical experts who serve as scientific advisors: Dr. Mark Lebwohl, dean for clinical therapeutics, Icahn School of Medicine at Mount Sinai; and Dr. Bruce Strober, clinical professor, Department of Dermatology at Yale University.

VedaBio Strengthens Management Team

Retrieved on: 
Wednesday, March 6, 2024

He previously held the role of Executive Chairman, President and Chief Operating Officer at VedaBio.

Key Points: 
  • He previously held the role of Executive Chairman, President and Chief Operating Officer at VedaBio.
  • “It is a privilege to serve a team that is truly operating at the forefront of scientific innovation, as we work together to create a fundamental new model in the field of molecular detection,” said Fred Sweeney, PhD, President and Chief Executive Officer, VedaBio.
  • “I am continuously impressed by the executive and scientific talent of the VedaBio team.
  • The VedaBio team shares a deep commitment to the mission of revolutionizing molecular detection and to empowering major advances across multiple applications,” said Craig Asher, Lead Director of VedaBio and Managing Director, OMX Ventures.

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink

Retrieved on: 
Friday, March 1, 2024

The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink.

Key Points: 
  • The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink.
  • The Offer is now scheduled to expire at 5:00 p.m., New York time, on April 30, 2024, unless the Offer is extended or earlier terminated.
  • These Shares and ADSs collectively represent approximately 95.2% of the outstanding Shares as of such time.
  • Olink shareholders who have already tendered their Shares or ADSs of Olink do not have to re-tender their Shares or ADSs or take any other action as a result of the extension of the expiration time of the Offer.

Next-Generation Safety: Radiation Detection Company Announces Availability of New Bluetooth Digital Dosimeter to Eliminate Shipping Exchanges and Improve Dose Visibility

Retrieved on: 
Friday, March 1, 2024

NetDose’s digital technology offers real time radiation monitoring using Bluetooth technology, eliminating the need to ship dosimeters back and forth to a laboratory for processing.

Key Points: 
  • NetDose’s digital technology offers real time radiation monitoring using Bluetooth technology, eliminating the need to ship dosimeters back and forth to a laboratory for processing.
  • The combination of leading technology from Thermo Fisher and 75 years of dosimetry service experience from RDC is sure to deliver incredible value for our customers,” said Ryan Turk, CEO, Radiation Detection Company.
  • “My thorough testing of the NetDose device has left me impressed by its exceptional reproducibility and precision.
  • With a detection limit reaching below 1 mrem, the NetDose dosimeter stands as a true technological advancement, transforming the landscape of external radiation dosimetry in ways unparalleled in the market,” said Chris Passmore, CTO, Radiation Detection Company.

Medidata and Thermo Fisher Scientific’s PPD Clinical Research Business Collaborate to Accelerate Clinical Trials Innovation

Retrieved on: 
Wednesday, February 28, 2024

Medidata , a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, today announced it has renewed its relationship with the PPD clinical research business of Thermo Fisher Scientific Inc.

Key Points: 
  • Medidata , a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, today announced it has renewed its relationship with the PPD clinical research business of Thermo Fisher Scientific Inc.
  • The agreement features the Medidata Platform , as well as Medidata Adjudicate and additional Medidata Rave product offerings that support the PPD clinical research business in advancing its customers’ drug development programs.
  • A key element of this relationship is the evolution of PPD TrueCast , a business solution powered by Medidata AI that shortens study timelines by combining patient recruitment and site performance data to deliver powerful predictive models and advanced analytics.
  • “Over the past 15 years, we have built a valued connection with the PPD clinical research business to enhance visibility and decision-making during clinical trials,” said Janet Butler, executive vice president and head of global sales, Medidata.

Thermo Fisher Scientific to Present at TD Cowen 44th Annual Health Care Conference on March 6, 2024

Retrieved on: 
Wednesday, February 28, 2024

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the TD Cowen Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. (EST).

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the TD Cowen Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. (EST).
  • You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .

Thermo Fisher Scientific Increases Quarterly Dividend

Retrieved on: 
Wednesday, February 21, 2024

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on April 15, 2024, to shareholders of record as of March 15, 2024.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on April 15, 2024, to shareholders of record as of March 15, 2024.
  • This reflects an 11% increase over the previous dividend payment of $0.35.